Skip to main content
Premium Trial:

Request an Annual Quote

MDxHealth, HistoGeneX Collaborate on PharmacoMDx Testing Services

NEW YORK (GenomeWeb News) – MDx Health and HistoGeneX today announced a collaboration to provide molecular diagnostic testing services to drug manufacturers and oncologists.

Under the terms of the deal, MDxHealth will combine its epigenetics technologies with HistoGeneX's pharmacodiagnostic services. HistoGeneX's laboratory in Belgium will also provide MGMT methylation service testing for MDxHealth's clients.

MDxHealth's PharmacoMDx services use next-generation sequencing and deep sequencing technology for the discovery of epigenetics-based diagnostic and personalized therapeutic products.

"The collaboration with HistoGeneX further broadens our PharmacoMDx services on a global basis and expands upon our biomarker discovery program at the Center of Pharmaco (epi)Genomics, a joint-venture with Ghent University," MDx CEO Jan Groen said in a statement. "HistoGeneX has established a strong reputation in the pharma industry, [and] combining their Belgium-based CLIA certified laboratory services and expansive test menu with our US-based CLIA laboratory and next-gen epigenetic capabilities will enable both organizations to leverage our respective networks and grow our customer base."

HistoGeneX offers histology, pathology, and molecular diagnostic services for pharmaceutical and hospital customers.

Financial and other terms were not disclosed.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.